All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

14

2023 to 2026

Breakthrough

3

Accelerated

1

Priority review

6

Orphan

4

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202331
202430
202540
202621

14 approvals

Newest first. Hover a badge for what it means.

  • Gwyn Lo (Ethinyl Estradiol, Norelgestromin) · Viatris SpecialtyJul 28, 2026
    Original approval · NDA 219990Approval letter
  • Lumvoa (Veligrotug-Vvze) · Viridian Therapeutics INCJun 26, 2026
    Original approval · BLA 761530NovelBreakthrough therapyPriority reviewApproval letter

    To treat thyroid eye disease

  • Veppanu (Vepdegestrant) · Rigel PharmsMay 1, 2026
    Original approval · NDA 219835NovelApproval letter

    To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

  • Lynkuet (Elinzanetant) · Bayer HlthcareOct 24, 2025
    Original approval · NDA 219469NovelApproval letter

    To treat moderate-to-severe vasomotor symptoms due to menopause

  • Inluriyo (Imlunestrant Tosylate) · Eli Lilly and COSep 25, 2025
    Original approval · NDA 218881NovelApproval letter

    To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

  • Palsonify (Paltusotine Hydrochloride) · CrineticsSep 25, 2025
    Original approval · NDA 219070NovelOrphanApproval letter

    To treat acromegaly in adults who had an inadequate response to surgery and/or for whom surgery is not an option

  • Miudella (Copper) · Sebela Womens HlthFeb 24, 2025
    Original approval · NDA 218201Approval letter
  • Crenessity (Crinecerfont) · NeurocrineDec 13, 2024
    Original approval · NDA 218808NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat classic congenital adrenal hyperplasia

  • Yorvipath (Palopegteriparatide) · Ascendis Pharma BoneAug 9, 2024
    Original approval · NDA 216490NovelPriority reviewOrphanApproval letter

    To treat hypoparathyroidism

  • Rezdiffra (Resmetirom) · MadrigalMar 14, 2024
    Original approval · NDA 217785NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter

    To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring

  • Ngenla (Somatrogon-Ghla) · Pfizer Ireland PharmaceuticalsJun 27, 2023
    Original approval · BLA 761184NovelOrphanApproval letter

    To treat growth failure due to inadequate secretion of endogenous growth hormone

  • Veozah (Fezolinetant) · AstellasMay 12, 2023
    Original approval · NDA 216578NovelPriority reviewApproval letter

    To treat moderate to severe hot flashes caused by menopause

  • Adrenalin (Epinephrine) · Ph HealthApr 21, 2023
    Original approval · NDA 215875Approval letter
  • Orserdu (Elacestrant Hydrochloride) · Stemline TherapJan 27, 2023
    Original approval · NDA 217639NovelPriority reviewApproval letter

    To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.